LLY vs. QCOM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LLY and QCOM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | QCOM |
|---|---|---|
| Company Name | Eli Lilly and Company | QUALCOMM Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry | Pharmaceuticals | Semiconductors & Semiconductor Equipment |
| Market Capitalization | 623.33 billion USD | 168.78 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 1, 1972 | December 13, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LLY and QCOM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | QCOM |
|---|---|---|
| 5-Day Price Return | -1.12% | 0.11% |
| 13-Week Price Return | -2.78% | 6.14% |
| 26-Week Price Return | -19.81% | -10.73% |
| 52-Week Price Return | -27.13% | -7.44% |
| Month-to-Date Return | -6.05% | 6.58% |
| Year-to-Date Return | -9.93% | 1.82% |
| 10-Day Avg. Volume | 5.47M | 6.59M |
| 3-Month Avg. Volume | 4.51M | 8.23M |
| 3-Month Volatility | 40.35% | 27.79% |
| Beta | 0.45 | 1.24 |
Profitability
Return on Equity (TTM)
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
QCOM
42.85%
Semiconductors & Semiconductor Equipment Industry
- Max
- 52.74%
- Q3
- 23.49%
- Median
- 11.60%
- Q1
- 3.23%
- Min
- -20.69%
In the upper quartile for the Semiconductors & Semiconductor Equipment industry, QCOM’s Return on Equity of 42.85% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
QCOM
26.77%
Semiconductors & Semiconductor Equipment Industry
- Max
- 44.17%
- Q3
- 22.38%
- Median
- 11.95%
- Q1
- 3.21%
- Min
- -25.16%
A Net Profit Margin of 26.77% places QCOM in the upper quartile for the Semiconductors & Semiconductor Equipment industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
QCOM
27.54%
Semiconductors & Semiconductor Equipment Industry
- Max
- 58.03%
- Q3
- 27.84%
- Median
- 12.45%
- Q1
- 5.15%
- Min
- -28.61%
QCOM’s Operating Profit Margin of 27.54% is around the midpoint for the Semiconductors & Semiconductor Equipment industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | LLY | QCOM |
|---|---|---|
| Return on Equity (TTM) | 88.36% | 42.85% |
| Return on Assets (TTM) | 16.02% | 20.96% |
| Net Profit Margin (TTM) | 25.91% | 26.77% |
| Operating Profit Margin (TTM) | 32.37% | 27.54% |
| Gross Profit Margin (TTM) | 82.64% | 55.68% |
Financial Strength
Current Ratio (MRQ)
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
QCOM
3.19
Semiconductors & Semiconductor Equipment Industry
- Max
- 8.42
- Q3
- 4.70
- Median
- 2.75
- Q1
- 2.07
- Min
- 1.04
QCOM’s Current Ratio of 3.19 aligns with the median group of the Semiconductors & Semiconductor Equipment industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
QCOM
0.54
Semiconductors & Semiconductor Equipment Industry
- Max
- 1.09
- Q3
- 0.45
- Median
- 0.22
- Q1
- 0.01
- Min
- 0.00
QCOM’s leverage is in the upper quartile of the Semiconductors & Semiconductor Equipment industry, with a Debt-to-Equity Ratio of 0.54. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
QCOM
38.40
Semiconductors & Semiconductor Equipment Industry
- Max
- 174.00
- Q3
- 81.10
- Median
- 27.22
- Q1
- 7.28
- Min
- -4.26
QCOM’s Interest Coverage Ratio of 38.40 is positioned comfortably within the norm for the Semiconductors & Semiconductor Equipment industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | LLY | QCOM |
|---|---|---|
| Current Ratio (MRQ) | 1.28 | 3.19 |
| Quick Ratio (MRQ) | 0.53 | 2.38 |
| Debt-to-Equity Ratio (MRQ) | 2.18 | 0.54 |
| Interest Coverage Ratio (TTM) | 20.36 | 38.40 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LLY
0.77%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
QCOM
2.27%
Semiconductors & Semiconductor Equipment Industry
- Max
- 4.16%
- Q3
- 1.78%
- Median
- 0.74%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.27%, QCOM offers a more attractive income stream than most of its peers in the Semiconductors & Semiconductor Equipment industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
QCOM
32.79%
Semiconductors & Semiconductor Equipment Industry
- Max
- 196.12%
- Q3
- 87.72%
- Median
- 26.57%
- Q1
- 0.00%
- Min
- 0.00%
QCOM’s Dividend Payout Ratio of 32.79% is within the typical range for the Semiconductors & Semiconductor Equipment industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | LLY | QCOM |
|---|---|---|
| Dividend Yield (TTM) | 0.77% | 2.27% |
| Dividend Payout Ratio (TTM) | 36.46% | 32.79% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
47.48
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
QCOM
14.43
Semiconductors & Semiconductor Equipment Industry
- Max
- 109.37
- Q3
- 57.11
- Median
- 28.95
- Q1
- 22.13
- Min
- 11.14
In the lower quartile for the Semiconductors & Semiconductor Equipment industry, QCOM’s P/E Ratio of 14.43 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
LLY
12.30
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
QCOM
3.86
Semiconductors & Semiconductor Equipment Industry
- Max
- 16.09
- Q3
- 10.10
- Median
- 4.82
- Q1
- 2.60
- Min
- 0.93
QCOM’s P/S Ratio of 3.86 aligns with the market consensus for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
QCOM
6.35
Semiconductors & Semiconductor Equipment Industry
- Max
- 13.56
- Q3
- 6.75
- Median
- 3.68
- Q1
- 1.89
- Min
- 0.60
QCOM’s P/B Ratio of 6.35 is within the conventional range for the Semiconductors & Semiconductor Equipment industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | LLY | QCOM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 47.48 | 14.43 |
| Price-to-Sales Ratio (TTM) | 12.30 | 3.86 |
| Price-to-Book Ratio (MRQ) | 40.43 | 6.35 |
| Price-to-Free Cash Flow Ratio (TTM) | 326.03 | 14.38 |